Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TCMD vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: TCMD 6 – 0 BMRA Matrix Metrics: TCMD 9 – 1 BMRA

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TCMD carries a Unified Composite Score of 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TCMD vs BMRA
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$26.36
-1.68% 1D
Market Cap $601.1M
TTM Revenue $356M
Forward P/E 18.2x
Beta / 30D Vol 1.07β · 53% Vol
Unified Composite Score
25.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 66.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.3% over 20 days), RSI 61
RSI-14: 60.6 · SMA20: $24.98 · SMA50: $23.45
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (TCMD 6 – 0 BMRA)

Columns: Metric · TCMD · BMRA
1. Valuation Multiples TCMD
Forward P/E 18.2x N/M
Trailing P/E 26.1x N/M
PEG Ratio 17.79x N/M
EV / Revenue 1.5x 1.1x
2. Growth & Scale TCMD
Revenue Growth (YoY) +7.1% -8.3%
Earnings Growth (YoY) -13.9% +0.0%
TTM Revenue (USD) $356M $4.3M
Market Cap $601.1M $6.0M
3. Profitability & Quality TCMD
Gross Margin 77.0% 0.9%
Operating Margin 9.4% -125.2%
Net Profit Margin 6.7% -115.5%
Return on Equity (ROE) 11.0% -113.8%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) $29M -$3.2M
Cash Flow Margin 8.1% -73.5%
Net Cash / Leverage $58M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 54.9% (15th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity 67.6% of Rev ($241M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TCMD (9) vs BMRA (1)
Institutional Metric TCMD BMRA Criterion Row Edge
Market Capitalization
Scale
$601.1M $6.0M Larger Scale TCMD
Trailing P/E Ratio
Valuation
26.1x N/M Lower Multiple TCMD
Forward P/E Ratio
Valuation
18.2x N/M Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+7.1% -8.3% Higher Growth TCMD
Operating Margin (TTM)
Profitability
9.4% -125.2% Higher Margin TCMD
Net Profit Margin
Profitability
6.7% -115.5% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
11.0% -113.8% Higher ROE TCMD
52-Week Range Position
Momentum
34% ($21–$38) 4% ($1–$3) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
1.07β · 53% Vol 0.67β · 62% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
25.0 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$356M $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.0% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.79x PEG · 1.5x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$29M ($58M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +45.24 pp
TCMD: +17.05% · BMRA: -28.19%
3M Horizon TCMD +27.49 pp
TCMD: +10.52% · BMRA: -16.97%
6M Horizon TCMD +52.42 pp
TCMD: +11.46% · BMRA: -40.96%
1Y Horizon TCMD +55.03 pp
TCMD: +8.17% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TCMD Revenue BMRA Revenue TCMD Op. Margin BMRA Op. Margin Margin Leader
FY2019 $190M $10M 5.5% -46.4% TCMD
FY2020 $190M $10M -1.9% -41.0% TCMD
FY2021 $210M $10M -0.8% -104.2% TCMD
FY2022 $250M $20M -5.2% -24.0% TCMD
FY2023 $270M $10M 6.6% -135.3% TCMD
FY2024 $290M $10M 7.6% -117.6% TCMD
FY2025 $330M $10M 8.9% -96.7% TCMD
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TCMD CONSOLIDATION
94d in phase · OBV ACCUMULATION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $601.1M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TCMD vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TCMD carries a Unified Composite Score of 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin), whereas BMRA carries 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY). Technical & Structure Timing Caution: TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TCMD leads the Growth & Scale pillar: TCMD posts +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), TCMD cumulative revenue shifted +73.7% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, TCMD deploys 67.6% of Rev ($241M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

TCMD screens cheaper on headline valuation multiples. TCMD trades at 18.2x Forward P/E, 26.1x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TCMD (11.0% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 53% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.